Clinical trials: Stage III Melanoma
Melanoma (Skin)
Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma
RATIONALE: Drugs used in chemotherapy, such as fludarabine, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00091143
- Testing
- gp100 antigen, incomplete Freund's adjuvant, keyhole limpet hemocyanin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Providence Cancer Center, Earle A. Chiles Research Institute
Melanoma (Skin)
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells…
- Trial name
- NCT00118274
- Testing
- incomplete Freund's adjuvant, melanoma helper peptide vaccine, multi-epitope melanoma peptide vaccine
- Where
- 3 sites in United States
- Volunteers
- 170 people
- Sponsor
- Craig L Slingluff, Jr
Adjuvant, Stage III Malignant Melanoma
Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon
The study protocol is being conducted to compare intermittent high-dose i.v. administation of interferon alpha-2b with the standard high-dose treatment by Kirkwood with distant metastasis free survival (DMFI) as a primary…
- Conditions
- Adjuvant, Stage III Malignant Melanoma, Interferon Alpha, Therapy
- Trial name
- NCT00226408
- Testing
- Interferon-alpha-2b
- Where
- 13 sites in Germany
- Volunteers
- 600 people
- Sponsor
- Dermatologic Cooperative Oncology Group
Cutaneous Melanoma
Minimal SN Tumor Burden
The purpose of this registry is to collect data in order to discover whether melanoma patients with minimal SN tumor burden should undergo a complete lymph node dissection (CLND) or not.
- Trial name
- Minitub (NCT01942603)
- Where
- 22 sites in Belgium, France and 8 more
- Volunteers
- 296 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Stage III Melanoma, Stage IV Cutaneous Melanoma
Leveraging ctDNA Analysis to Improve Early Detection of Cancer Recurrence in the High-Risk Melanoma Setting
To generate meaningful data regarding ctDNA that would infer risk of recurrence in stage III melanoma patients.
- Trial name
- NCT05079113
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Case Comprehensive Cancer Center
Malignant Melanoma
Neoadjuvant L19IL2/L19TNF- Pivotal Study
Phase III, open-label, randomized, controlled multi-center study of the efficacy of L19IL2/L19TNF neoadjuvant intratumoral treatment in Stage III B/C melanoma patients.
- Trial name
- Pivotal (NCT02938299)
- Testing
- L19IL2 + L19TNF, Surgery
- Where
- 22 sites in France, Germany and 2 more
- Volunteers
- 214 people
- Sponsor
- Philogen S.p.A.
Melanoma
Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma
The purpose of this study is to investigate the pharmacokinetics (PK) similarity of Bmab1700 (an intended nivolumab biosimilar), compared with United States (US)-licensed Opdivo, in participants after complete surgical removal of…
- Trial name
- NCT07476326
- Testing
- Bmab1700, Opdivo
- Where
- 46 sites in Brazil, Chile and 8 more
- Volunteers
- 120 people
- Sponsor
- Biocon Biologics UK PLC
Melanoma (Skin)
Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well dasatinib works in treating patients with locally advanced or…
- Trial name
- NCT00700882
- Testing
- dasatinib
- Where
- 153 sites in United States
- Volunteers
- 81 people
- Sponsor
- Eastern Cooperative Oncology Group
Melanoma, Skin Cancer
Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection
In this study, we want to find out how likely it is for temozolomide to shrink melanoma tumors that have spread only to areas that could be removed by surgery.
- Conditions
- Melanoma, Skin Cancer, Cancer
- Trial name
- NCT00588341
- Testing
- Temozolomide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
This phase I/II trial studies the side effects and best dose of nivolumab when given with or without ipilimumab to see how well they work in treating younger patients with solid tumors or sarcomas that have come back (recurrent)…
- Conditions
- Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Hodgkin Lymphoma, Recurrent Malignant Solid Neoplasm
- Trial name
- NCT02304458
- Testing
- Ipilimumab, Laboratory Biomarker Analysis, Nivolumab
- Where
- 25 sites in United States, Canada
- Volunteers
- 140 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Melanoma, Stage IIIA Melanoma
Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery
This phase I trial studies the side effects and best dose of cabozantinib-s-malate when given together with vemurafenib in treating patients with solid tumors or melanoma that is metastatic or that cannot be removed by surgery.
- Conditions
- Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma
- Trial name
- NCT01835184
- Testing
- cabozantinib-s-malate, vemurafenib, laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma (Skin)
PET and CT Scans to Evaluate Patients With Stage III or Stage IV Melanoma
RATIONALE: Diagnostic procedures may improve the ability to detect metastatic melanoma and to determine the extent of disease. PURPOSE: Phase II trial to evaluate the effectiveness of PET and CT scans to detect metastatic disease…
- Trial name
- NCT00004152
- Testing
- iodinated contrast dye, computed tomography, positron emission tomography
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Melanoma Stage III, Melanoma Stage Iv
Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma
Open-label, single-arm, multi-center, Phase IIa study to evaluate the efficacy, safety, and immunological response of OBP 301 in patients with unresectable/unresected metastatic melanoma.
- Trial name
- NCT03190824
- Testing
- OBP-301
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Syneos Health
Cancer, Melanoma Stage III
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
KB707-01 is a Phase 1/2, open-label, multicenter, dose escalation and expansion study. The study will evaluate the safety and tolerability of KB707 in adults with locally advanced or metastatic solid tumors who have progressed on…
- Conditions
- Cancer, Melanoma Stage III, Melanoma Stage IV, Cutaneous Melanoma
- Trial name
- NCT05970497
- Testing
- KB707, Opdualag, KEYTRUDA ®( Pembrolizumab)
- Where
- 15 sites in United States
- Volunteers
- 240 people
- Sponsor
- Krystal Biotech, Inc.
Stage IV Resectable Melanoma
Stage IV Surgery Versus Best Medical Therapy
This study will establish the role of surgical versus nonsurgical approaches in patients whose melanoma has spread to distant sites.
- Trial name
- STG4SURG (NCT01013623)
- Testing
- Surgery, Surgery plus 2 adjuvant doses of BCG, best medical therapy
- Where
- 19 sites in United States, Australia and 3 more
- Volunteers
- 12 people
- Sponsor
- Saint John's Cancer Institute
Metastatic Melanoma
A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients
The purpose of this study is to test the combination of Ipilimumab and GM-CSF. Both ipilimumab and GM-CSF are intended to work with the body's own immune system to attack melanoma cells in the body.
- Trial name
- NCT02009397
- Testing
- Ipilimumab, GM-CSF
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Louisville
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Melanoma
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
The purpose of this study is to learn about the effects of three study medicines (encorafenib, binimetinib, and pembrolizumab) given together for the treatment of melanoma that: is advanced or metastatic (spread to other parts of…
- Trial name
- NCT04657991
- Testing
- Encorafenib, Binimetinib, Pembrolizumab
- Where
- 151 sites in United States, Argentina and 25 more
- Volunteers
- 257 people
- Sponsor
- Pfizer
Melanoma (Skin)
Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining different types of biological therapies may kill more tumor cells.
- Trial name
- NCT00004022
- Testing
- aldesleukin, autologous tumor cell vaccine, muromonab-CD3
- Where
- United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Malignant Melanoma
Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma
The combination of TMZ and DAC may effect dual modulation of DNA repair genes resulting in improved clinical response.
- Trial name
- UPCI-07-008 (NCT00715793)
- Testing
- Decitabine, Temozolomide, biopsy
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Hussein Tawbi